Search - Université de Rennes Access content directly

Filter your results

26 Results
authFullName_s : Hervé Tilly
Image document

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

Vincent Ribrag , Serge Koscielny , Jacques Bosq , Thibaut Leguay , Olivier Casasnovas et al.
The Lancet, 2016, 387 (10036), pp.2402 - 2411. ⟨10.1016/S0140-6736(15)01317-3⟩
Journal articles inserm-01419476v1

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma

Steven Le Gouill , Catherine Thieblemont , Lucie Oberic , Anne Moreau , Krimo Bouabdallah et al.
New England Journal of Medicine, 2017, 377 (13), pp.1250-1260. ⟨10.1056/NEJMoa1701769⟩
Journal articles hal-02329536v1

Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay: A CALYM Study.

Sylvain Mareschal , Philippe Ruminy , Cristina Bagacean , Vinciane Marchand , Marie Cornic et al.
Journal of Molecular Diagnostics, 2015, 17 (3), pp.273-283. ⟨10.1016/j.jmoldx.2015.01.007⟩
Journal articles hal-01145953v1

A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma

Bertrand Coiffier , Catherine Thieblemont , Sophie de Guibert , Jehan Dupuis , Vincent Ribrag et al.
British Journal of Haematology, 2016, 173 (5), pp.722-730. ⟨10.1111/bjh.13992⟩
Journal articles hal-01295660v1

Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study

Hervé Tilly , Franck Morschhauser , Olivier Casasnovas , Thierry Jo Molina , Pierre Feugier et al.
The Lancet Haematology, 2018, 5 (9), pp.e403-e410. ⟨10.1016/S2352-3026(18)30131-5⟩
Journal articles hal-02329073v1

Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA

Roch Houot , Carole Soussain , Hervé Tilly , Corinne Haioun , Catherine Thieblemont et al.
Annals of Oncology, 2016, 27 (7), pp.1349-50. ⟨10.1093/annonc/mdw138⟩
Journal articles hal-01295653v1

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases

Sydney Dubois , Pierre-Julien Viailly , Elodie Bohers , Philippe Bertrand , Philippe Ruminy et al.
Clinical Cancer Research, 2017, 23 (9), pp.2232-2244. ⟨10.1158/1078-0432.CCR-16-1922⟩
Journal articles hal-01526582v1

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.

Emilie Reboursiere , Fabien Le Bras , Charles Herbaux , Emmanuel Gyan , Aline Clavert et al.
Oncotarget, 2016, 7 (51), pp.85573-85583. ⟨10.18632/oncotarget.10764⟩
Journal articles hal-01475957v1

Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study

Fabrice Jardin , Anaïs Pujals , Laura Pelletier , Elodie Bohers , Vincent Camus et al.
Blood, 2015, 126 (23), pp.129
Journal articles hal-01300803v1
Image document

Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group

Christophe Bonnet , Jehan Dupuis , Hervé Tilly , Thierry Lamy , Christophe Fruchart et al.
Cancers, 2022, 14 (7), pp.1761. ⟨10.3390/cancers14071761⟩
Journal articles hal-03660656v1

Abstract 4810: Exome sequencing of refractory diffuse large B-cell lymphomas highlights candidate genes for targeted resequencing

Sylvain Mareschal , Pierre-Julien Viailly , Philippe Bertrand , Elodie Bohers , Jean-Philippe Jais et al.
AACR 106th Annual Meeting 2015, Apr 2015, Philadelphia, PA, United States. 75 (15 Supplement), pp.4810--4810, 2015, ⟨10.1158/1538-7445.AM2015-4810⟩
Conference poster hal-01300809v1
Image document

Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area

Caroline Gay , Richard Delarue , Noël Milpied , Lucie Oberic , Bertrand Coiffier et al.
Blood, 2017, 129 (20), pp.2811-2813. ⟨10.1182/blood-2017-02-766147⟩
Journal articles hal-01558813v1
Image document

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma a phase II LYSA study

Roch Houot , Guillaume Cartron , Fontanet Bijou , Sophie de Guibert , Gilles A Salles et al.
Leukemia, 2019, 33 (3), pp.776-780. ⟨10.1038/s41375-018-0282-y⟩
Journal articles hal-01903056v1
Image document

An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma

Franck Morschhauser , Gilles Salles , Steven Le Gouill , Hervé Tilly , Catherine Thieblemont et al.
Blood, 2018, 132 (14), pp.1486 - 1494. ⟨10.1182/blood-2018-05-853499⟩
Journal articles hal-01928199v1

Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study

Sydney Dubois , Bruno Tesson , Pierre-Julien Viailly , Thierry Molina , Christiane Copie-Bergman et al.
Blood, 2015, 126 (23), pp.1472
Journal articles hal-01300813v1
Image document

Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis.

Céline Pangault , Patricia Amé-Thomas , Philippe Ruminy , Delphine Rossille , Gersende Caron et al.
Leukemia, 2010, 24 (12), pp.2080-9. ⟨10.1038/leu.2010.223⟩
Journal articles inserm-00570274v1

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and Non-L265P Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases

Sydney Dubois , Pierre-Julien Viailly , Elodie Bohers , Philippe Bertrand , Philippe Ruminy et al.
58th ASH Annual Meeting and Exposition, Dec 2016, San Diego, CA, United States. 128 (22), pp.4097-4097, 2016, ⟨10.1182/blood.V128.22.4097.4097⟩
Conference poster hal-02482497v1

Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.

Judith Trotman , Marion Fournier , Thierry Lamy , John Francis Seymour , Anne Sonet et al.
Journal of Clinical Oncology, 2011, 29 (23), pp.3194-200. ⟨10.1200/JCO.2011.35.0736⟩
Journal articles hal-00741692v1
Image document

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma

Roch Houot , Viola Poeschel , Bettina Altmann , Stephanie Angel , Lorenz Thurner et al.
HemaSphere, 2022, 6 (2), ⟨10.1097/HS9.0000000000000672⟩
Journal articles hal-03575963v1

Abstract 4947: HACE1 is a putative tumor suppressor gene in B-cell lymphomagenesis down-regulated by both deletion and epigenetic mechanisms

Abdelilah Bouzelfen , Marion Alcantara , Hafid Kora , Philippe Bertrand , Sylvain Mareschal et al.
AACR 106th Annual Meeting 2015, Apr 2015, Philadelphia, PA, United States. 75 (15 Supplement), pp.4947--4947, 2015, ⟨10.1158/1538-7445.AM2015-4947⟩
Conference poster hal-01300808v1
Image document

Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study

Sydney Dubois , Pierre-Julien Viailly , Sylvain Mareschal , Elodie Bohers , Philippe Bertrand et al.
Clinical Cancer Research, 2016, 22 (12), pp.2919--2928. ⟨10.1158/1078-0432.CCR-15-2305⟩
Journal articles hal-01343064v1

Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

Hervé Ghesquières , Susan L. Slager , Fabrice Jardin , Amelie S. Veron , Yan W. Asmann et al.
Journal of Clinical Oncology, 2015, 33 (33), pp.3930-3937. ⟨10.1200/JCO.2014.60.2573⟩
Journal articles hal-01217986v1

Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma

Sylvain Mareschal , Sydney Dubois , Pierre-Julien Viailly , Philippe Bertrand , Elodie Bohers et al.
Genes, Chromosomes & Cancer, 2016, 55 (3), pp.251-267. ⟨10.1002/gcc.22328⟩
Journal articles istex hal-01237083v1
Image document

Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group

Steven Le Gouill , Asma Beldi-Ferchiou , Marion Alcantara , Victoria Cacheux , Violaine Safar et al.
Lancet Haematology, 2020, 7 (11), pp.e798-e807. ⟨10.1016/S2352-3026(20)30291-X⟩
Journal articles hal-03012903v1
Image document

Somatic mutations of cell-free circulating DNA detected by Next Generation Sequencing reflect the genetic changes in both Germinal Center B-Cell like and Activated B-Cell like Diffuse Large B-Cell Lymphoma tumors at the time of diagnosis

Elodie Bohers , Pierre Julien Viailly , Sydney Dubois , Philippe Bertrand , Catherine Maingonnat et al.
Haematologica, 2015, 100 (7), pp.e280-e284. ⟨10.3324/haematol.2015.123612⟩
Journal articles hal-01132460v1
Image document

Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study

Franck Morschhauser , Steven Le Gouill , Pierre Feugier , Sarah Bailly , Emmanuelle Nicolas-Virelizier et al.
The Lancet Haematology, 2019, 6 (8), pp.e429-e437. ⟨10.1016/S2352-3026(19)30089-4⟩
Journal articles hal-02586078v1